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TO THE EDITOR
Cyclosporine A (CsA) has long been
recognized as a potent hair growth
stimulator in both humans and rodent.
The induction of a dose-dependent
hypertrichosis is one of the most
frequent adverse effects of long-term
CsA therapy (Lutz, 1994). However, it is
unclear how this immunosuppressant
induces hypertrichosis in patients or
stimulates hair growth in human scalp
skin transplanted on nude mice (Gilhar
et al., 1988; Gilhar et al., 1991).
Previous murine studies have shown
that CsA potently modulates hair follicle
(HF) cycling by inducing anagen in
telogen HFs and by suppressing the
development of catagen in anagen HFs
(Paus et al., 1989, 1994, 1996). CsA
directly targets human HFs, promoting
hair shaft production and potentially
prolonging anagen in organ-cultured
human scalp HFs (Taylor et al., 1993).
CsA is thought to act by forming a
complex with cyclophilin A, which in
turn binds to and inhibits calcineurin
(CN), preventing the dephosphorylation
of target proteins, which include ion
channels, receptors, and transcription
factors (Wu et al., 2007; Li et al., 2011).
Among the latter, members of the
nuclear factor of activated T-cells
(NFAT) family, which controls a wide
range of cellular functions that include
proliferation, apoptosis, and differentia-
tion, are thought to be most important
(Wu et al., 2007; Li et al., 2011). The
hypothesis that CN inhibition has a role
in the hair cycle–modulatory effects of
CsA is supported by work in mice
(Gafter-Gvili et al., 2003). It was also
shown that NFATc1 is activated in
murine epithelial HF stem cells
(HFSCs) where it maintains HF
quiescence (Horsley et al., 2008).
Conversely, NFATc2 inhibits the proli-
feration of murine hair matrix (HM)
keratinocytes in a cyclin G2 and
p21waf/cip1 – dependent manner (Gafter-
Gvili et al., 2003; Fujimura et al., 2011).
In mice, CsA releases the inhibition of
HFSCs by NFATc1, thus promoting
anagen (Horsley et al., 2008). Catagen
development in rats is prevented by
CsA suppressing NFATc2 activity in the
anagen HM (Fujimura et al., 2011).
However, these concepts as well as
the intrafollicular expression pattern of
NFAT family members are derived from
rodent studies, and remain to be con-
ﬁrmed in human HFs.
As such, we initially sought to clarify
whether CsA inhibits catagen develop-
ment in human HFs. To investigate this,
normal human scalp HFs were stimu-
lated with CsA (6 days), applying
standardized quantitative (immuno-) his-
tomorphometry (Kloepper et al., 2010).
We used 10−7 M CsA, replicating a pre-
vious study and imitating the therapeutic
CsA plasma level (Taylor et al., 1993). In
addition, we analyzed the NFAT family
expression and localization in human
scalp HFs in response to CsA. HF sam-
ples were harvested with written informed
patient consent and with approval under
an institutional ethics license.
CsA stimulation for 6 days signiﬁ-
cantly enhanced hair shaft production
in normal human scalp HFs in vitro,
indicating that CsA-treated HFs retain
their (anagen-restricted) capacity to
generate a hair shaft (Figure 1a). This
was independently conﬁrmed through a
series of histological analysis (Figures
1b–g). Masson-Fontana histochemistry
demonstrated signiﬁcantly higher mela-
nin content in CsA-treated HFs
(melanogenesis is shut-off upon catagen
entry) (Figures 1b and c). Next, we
performed Ki-67/TUNEL dual immuno-
ﬂuorescence (Figure 1d). HM keratino-
cyte proliferation (Ki-67) was signiﬁ-
cantly higher following CsA treatment
(Figure 1e), whereas the number of
DAPI+ HM cells below Auber’s line
was also signiﬁcantly greater compared
with vehicle-treated HFs (Figure 1f).
The number of nuclei in the dermal
papilla (DP) stalk was assessed as an
indicator of ﬁbroblast emigration from
the DP (Kloepper et al., 2010), a
phenomenon occurring during catagen
development, which reduces DP
volume (Tobin et al., 2003). CsA
signiﬁcantly reduced the number of
DAPI+ nuclei in the stalk (Figure 1g),
indicating that fewer DP ﬁbroblasts
have emigrated and suggesting pro-
longed anagen duration following CsA
treatment. We also hypothesize that
CsA can promote hypertrichosis by
retaining inductive ﬁbroblasts within
the DP, thus enlarging DP volume and
thereby HM volume (Tobin et al.,
2003). This is supported by a recent
study demonstrating that CsA enlarges
the DP in mice (Lan et al., 2015).
We could not detect any signiﬁcant
differences in the expression of apoptosis
markers (TUNEL/Caspase-3) between CsA
and control HFs after 6 days of treatment
(Supplementary Figure S1 online). How-
ever, we show a signiﬁcant decrease
in caspase-3 mRNA following 6-hour
CsA incubation (Figure 1h). Collectively,
these results provide compelling evidence
that CsA inhibits spontaneous catagen
development in human HFs.
Next, intrafollicular NFATc1 and
NFATc2 proteins and gene expression
were assessed. In line with the reported
distribution in murine HFs (Horsley
et al., 2008), nuclear NFATc1 immuno-
reactivity (IR) was observed in the
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human HF bulge, suggesting that
NFATc1 is constitutively activated in
human HFSCs in situ during anagen
(Supplementary Figure S2 online).
Conversely, NFATc2 IR in human HFs
showed a very different expression
pattern than in rat HFs (Fujimura et al.,
2011), being localized to the cytoplasm
of the basal outer root sheath (Supple-
mentary Figure S2 online). Notably,
NFATc2 IR was absent from the human
anagen hair bulb (Supplementary Figure
S2 online). NFATc1 nuclear trans-
location was blocked following CsA-
treatment (Figure 2a), whereas NFATc2
remained cytoplasmic (Figure 2b). In
addition, only NFATc3 gene expression
was signiﬁcantly modulated by CsA treat-
ment (Figure 2c). Cytoplasmic (inactive)
NFATc3 IR was detected in the bulge
region of anagen HFs (Figure 2d).
To further examine the potential
involvement of NFATc2, we measured
the expression of the recognized
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Figure 1. Cyclosporine A (CsA) treatment inhibits catagen development. Human hair follicles (HFs) were cultured for 6 days with either CsA (10−7 M) or vehicle
control. CsA-treated HFs had signiﬁcantly greater hair shaft elongation on day 6 (n=39 HFs control, 43 HFs CsA; pooled from 4 male patients); (a). HF sections
were stained with Masson-Fontana (n= 19 HFs control, 20 HFs CsA; pooled from three patients); (b). CsA-treated HFs had signiﬁcantly higher melanin content (c).
HF sections were stained with Ki-67/TUNEL to asses additional parameters (n=13 HFs control, 15 HFs CsA; pooled from three patients); (d–g). CsA signiﬁcantly
increased proliferation (e) and total cell number (f), whereas signiﬁcantly decreased ﬁbroblast migration within the DP stalk (g). CsA signiﬁcantly decreased
CASP3 mRNA (6 hours incubation; n= 6 patient samples) (h). AL, Auber’s line; CASP3, caspase-3; DP, dermal papilla; Data expressed as mean± SEM; unpaired
t-test was performed for a, c, e–g; one sample t-test was performed for g; *Po0.05, **Po0.01, and ***Po0.001. Scale bar = 100 μm (b) and 50 μm (d).
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NFATc2 target genes, CCNG2 and
CDKN1A, which encode for cyclin G2
and p21waf/cip1, respectively (Fujimura
et al., 2011). Following 6-hour CsA
treatment, no difference in CCNG2
and CDKN1A mRNA levels was found
(Supplementary Figure S3 online).
Our data provide deﬁnitive evidence
that CsA is capable of inhibiting catagen
development in human HFs. The mechan-
ism for CsA-induced anagen induction
identiﬁed in mice may also apply to
the human HF, given our demonstration
that activated NFATc1 is prominently
expressed in the human bulge. However,
our observation that the human anagen
bulb does not express NFATc2 protein
strongly suggests that other, NFATc2-inde-
pendent mechanisms underlie the catagen-
inhibitory properties of CsA. This is further
supported by our data demonstrating that
the transcription of classical NFATc2 target
genes are unaltered in response to CsA.
The current results caution against
extrapolating the mechanism for CsA-
dependent hair growth modulation in
the human HF from corresponding work
in rodents. Elucidating the mechanisms of
CsA-induced hypertrichosis in human
skin is of major translational relevance,
as the key genes and pathways may be
targeted directly for the therapeutic mod-
ulation of human hair growth, thus avoid-
ing use of this potent immunosuppressant.
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TO THE EDITOR
Generalized pustular psoriasis (GPP;
OMIM 614204) is a severe type of
psoriasis characterized by widespread
erythematous skin and sterile pustules
that affects up to 1.3% of psoriasis
patients (Takahashi et al., 2011). The
acute onset of GPP is typically associ-
ated with high-grade fever, rigor, and
toxicity. Acitretin is considered to be ﬁrst-
line therapy for GPP, and it appears to
provide better efﬁcacy as a single agent
in the treatment of pustular psoriasis
compared with psoriasis vulgaris (PV;
OMIM 177900) as a single agent treat-
ment (Sbidian et al., 2011). Using homo-
zygosity mapping and direct sequencing
in consanguineous Tunisian multiplex
families with autosomal recessive GPP,
Marrakchi et al. (2011) ﬁrst reported the
association between IL36RN and GPP.
A variety of missense and nonsense
changes in IL36RN have since been des-
cribed in European and Asian patients.
Individuals with an IL36RN mutation
show upregulated IL1 expression, which
likely accounts for the occurrence of
systemic inﬂammation and peripheral
neutrophilia, two cardinal features of
GPP (Onoufriadis et al., 2011). How-
ever, the percentages of IL36RN-nega-
tive patients have been reported to
range from 51% (Li et al., 2013) to 84%
(Setta-Kaffetzi et al., 2013), implying t
hat additional risk loci, genetic interac-
tions, and other factors account for the
remaining GPP occurrence. Recently,
Jordan et al. (2012) identiﬁed the
mutation c.413A4C (p.Glu138Ala) in
CARD14 in a child with sporadic, early-
onset GPP, which indicates that
CARD14 is another candidate gene
responsible for GPP.
Compared with GPP, PV has been
intensively studied, and numerous risk-
associated variants within 44 suscept-
ibility loci have been discovered (Tang
et al., 2014). Among these susceptibility
loci, IL36RN was not reported to be
associated with PV. Furthermore, HLA-
Cw6, the major susceptibility deter-
minant for PV, is not associated with
GPP (Grifﬁths and Barker, 2010).
To identify the relationship between
GPP and PV, further our understanding
of GPP, and detect other susceptibility
genes/loci, we performed a candidate
loci study in GPP patients. GPP cases
and healthy controls were recruited
from multiple hospitals in the central
areas of China (Shanghai and Shandong
provinces). The patients were isolated
individuals of Chinese origin with typi-
cal clinical presentations or pathologic
features. A total of 238 patients and 421
controls were included in the analysis.
The clinical characteristics of the cases
and controls are indicated in
Supplementary Table S1 online. The
study was approved by the Ethics
Committee of Fudan University Hua-
shan Hospital and was conducted
according to the principles of the
Declaration of Helsinki. All the partici-
pants signed informed consent about
this experiment. For the selection of the
single-nucleotide polymorphisms (SNPs),
we searched published genome-wide
association study (GWAS) on PV from
the GWAS catalog and summarized the
reported susceptibility loci. Using Hap-
Map data (Han Chinese in Beijing,
China), we identiﬁed the most signiﬁ-
cant SNPs of the linkage disequilibrium
(LD) region and excluded redundant and
monomorphic SNPs in Chinese popula-
tion; in total, 50 SNPs were ultimately
selected (Supplementary Table S2 online).
Allele detection was performed using
matrix-assisted laser desorption/ionization
time of ﬂight mass spectroscopy. The
mass spectrograms were analyzed with
MassARRAY TYPER software (Sequenom,
San Diego, CA). Minor allele frequency
was 41% with P40.01 for Hardy–
Weinberg equilibrium in the controls,
and SNPs with call rates higher than
95% in the cases or controls were used in
accordance with the SNP quality criteria.
For the association testing, the Armitage
trend test was employed to detect allelicAccepted article preview online 24 March 2015; published online 9 April 2015
Abbreviations: GPP, generalized pustular psoriasis; GWAS, genome-wide association study; IPA,
ingenuity pathway analysis; LD, linkage disequilibrium; OR, odds ratio; PV, psoriasis vulgaris; RAR,
retinoic acid receptor; SNP, single-nucleotide polymorphism
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